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Abstract 1 
Background: The fat mass and obesity-associated gene (FTO) rs9939609 A-allele is 2 
associated with higher acyl-ghrelin (AG) concentrations, higher energy intake and obesity, 3 
though exercise may mitigate rs9939609 A-allele linked obesity risk. Butyrylcholinesterase 4 
(BChE) hydrolyses AG to des-acyl-ghrelin (DAG), potentially decreasing appetite. However, 5 
the effects of the FTO rs9939609 genotype and exercise on BChE activity, AG, DAG and 6 
energy intake are unknown. 7 
Objective: We hypothesized that individuals homozygous for the obesity-risk A-allele (AAs) 8 
would exhibit higher postprandial AG and energy intake than individuals homozygous for the 9 
low obesity-risk T-allele (TTs), but that exercise would increase BChE activity and diminish 10 
these differences.  11 
Methods: Twelve AA and 12 TT normal weight males completed a control (8 hours rest) and 12 
an exercise (1 hour of exercise at 70% peak oxygen uptake, 7 hours rest) trial in a randomized 13 
cross-over design. A fixed meal was consumed at 1.5 hours and an ab ad libitum buffet meal 14 
at 6.5 hours. Appetite, appetite-related hormones, BChE activity and energy intake were 15 
assessed. 16 
Results: AAs displayed lower baseline BChE activity, higher baseline AG/DAG ratio, 17 
attenuated AG suppression after a fixed meal and higher ad libitum energy intake than TTs 18 
(ES ≥ 0.72, P ≤ 0.049). Exercise increased delta BChE activity in both genotypes (ES = 0.37, 19 
P = 0.004); however, exercise lowered AG and the AG/DAG ratio to a greater extent in AAs 20 
(P ≤ 0.023), offsetting the higher AG ghrelin profile observed in AAs during the control trial 21 
(ES ≥ 1.25, P ≤ 0.048). Exercise did not elevate energy intake in either genotype (P = 0.282).  22 
Conclusions: Exercise increases BChE activity, suppresses AG and the AG/DAG ratio and 23 
corrects the higher AG profile observed in obesity-risk AA individuals. These findings 24 
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suggest that exercise or other methods targeting BChE activity may offer a preventative 25 
and/or therapeutic strategy for AA individuals. 26 
 27 
Keywords: exercise; ghrelin; appetite; FTO gene; butyrylcholinesterase; obesity28 
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INTRODUCTION 29 
A cluster of single nucleotide polymorphisms (SNP) within intron one of the fat mass and 30 
obesity-associated gene (FTO) have been consistently associated with obesity (1–3). At the 31 
FTO rs9939609 SNP, homozygous obesity-risk A-allele carriers (AA) have a 1.7-fold higher 32 
risk for obesity compared to individuals homozygous for the T-allele (TT) (1). Compared 33 
with TTs, AA individuals exhibit lower postprandial satiety and higher energy intake (4–6). 34 
Karra et al. (7) also reported that AAs displayed an attenuated postprandial suppression of the 35 
orexigenic hormone acyl-ghrelin (AG) and appetite compared to TTs. These findings suggest 36 
the impaired postprandial suppression of AG might contribute to the higher energy intake and 37 
obesity risk in AAs.  38 
Acute bouts of moderate- to vigorous-intensity exercise acutely suppress both subjective 39 
appetite perceptions and circulating AG concentrations (8,9). In addition, circulating 40 
concentrations of the anorectic hormones PYY and GLP-1 are increased by a single exercise 41 
bout (9,10). These gut hormone changes are suggested to provoke the acute anorectic effect 42 
of exercise (8,9,11). Further to changes during the exercise bout, circulating AG 43 
concentrations remain suppressed while PYY and GLP-1 are elevated in the hours after 44 
exercise (8,9,11). Importantly, the lack of compensatory changes in hunger and appetite-45 
related hormones to an energy shortfall caused by exercise results in a short-term negative 46 
energy balance, which if sustained, could facilitate weight management (12). 47 
The serine hydrolase butyrylcholinesterase (BChE) regulates circulating ghrelin 48 
concentrations by hydrolyzing AG to des-acyl-ghrelin (DAG), which is suggested to have an 49 
anorexigenic effect (13). Recent studies indicate that reduced BChE activity leads to a higher 50 
AG/DAG ratio, greater food consumption and weight gain (14,15). However, less is known 51 
about the interplay between BChE, FTO rs9939609 and exercise in humans. One study 52 
6 
 
 
indicated that a single bout of light running increases BChE activity in humans (16), but 53 
further work is needed to examine if BChE activity is linked to FTO rs9939609 genotype and 54 
exercise-dependent changes in plasma ghrelin concentrations or appetite-related outcomes in 55 
humans.  56 
Our primary aim was to investigate the effect of the FTO rs9939609 genotype and exercise 57 
on circulating AG and DAG concentrations, BChE activity, appetite and energy intake in a 58 
group of normal-weight AA males and a matched-group of TT males. As a secondary aim, 59 
we examined the effect of exercise and/or the FTO rs9939609 genotype on plasma 60 
concentrations of leptin, PYY and GLP-1. We hypothesized that AAs would exhibit higher 61 
AG, appetite and energy intake compared to TTs, but exercise would increase BChE activity 62 
and suppress these rs9939609-related differences. 63 
PARTICIPANTS AND METHODS 64 
Participants 65 
The study was performed according to the principles set out in the Declaration of Helsinki 66 
and was approved by the Loughborough University ethical advisory committee. We recruited 67 
202 healthy, non-smoking males aged 18-50 y of mixed European descent who provided 68 
written informed consent to take part in a database study. Exclusion criteria were history of 69 
cardio-metabolic disease, medical or psychiatric conditions, substance abuse and food 70 
allergies. Participants’ height and body mass were measured, and waist circumference was 71 
assessed as the narrowest portion of the torso between the xiphoid process and the naval. 72 
Skinfold thickness was measured and body fat percentage was estimated (17). Habitual 73 
physical activity levels were assessed using the short form International Physical Activity 74 
Questionnaire (18) and eating behaviors and attitudes were assessed using the Three-Factor 75 
Eating Questionnaire (19). A venous blood sample was collected and DNA was extracted. All 76 
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DNA extractions from peripheral blood samples were performed using the QIAamp DNA 77 
Blood Midi Kit (Qiagen). Genotyping for rs9939609 was performed by LGC Limited 78 
(Hertfordshire, UK) using the KASP (KBioscience Competitive Allele-Specific PCR) SNP 79 
genotyping system (www.lgcgenomics.com/genotyping/kasp-genotyping-reagents/). Blind 80 
duplicates were used to detect possible DNA mix-up. From the database, we recruited a 81 
group of 12 AA and 12 TT participants (Table 1) for a randomized cross-over study 82 
(Supplementary Figure 1). Participants provided written informed consent if they were 83 
invited back and completed the study between January 2015 to February 2016. Further to the 84 
criteria mentioned, to be included in this trial, participants had to be weight stable (≤ 3 kg 85 
over previous 3 months) and habitually consumed breakfast on 5 or more days of the week in 86 
an attempt to reduce the influence of breakfast consumption on fasting ghrelin concentrations 87 
(20). Participants were also excluded if they presented any food allergies. Groups were 88 
matched for anthropometric indices, age and peak oxygen uptake (Table 1). The study is 89 
registered at clinicaltrials.gov as NCT03025347. 90 
Main trials 91 
Participants attended a preliminary measures and familiarization session prior to main trials. 92 
Body mass, height, body fat percentage, body mass index (BMI) and waist circumference 93 
were re-measured as described to confirm no substantial changes occurred from the database 94 
study. Participants performed submaximal incremental and peak oxygen uptake running tests 95 
on a motorized treadmill as described elsewhere (8). Individual running speed-oxygen uptake 96 
linear regression equations and peak oxygen uptake were used to calculate the running speed 97 
that corresponded to 70% of each participant’s peak oxygen uptake. Participants also 98 
completed a food preference questionnaire and were familiarized with the buffet meal, to 99 
reduce the risk of any changes in food intake due to novelty of the meal.  100 
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Next, in a randomized cross-over design stratified by rs9939609 genotype group, all 101 
participants completed two main trials separated by 7-14 days: exercise and control. Further 102 
to enrolling participants, the main investigator conducted the block randomization plan for 103 
each genotype from the website www.randomization.com and assigned participants to the 104 
order of trials completed. Participants were instructed to complete a weighed food diary in 105 
the 24 h before the first trial and replicate it in the 24 h before the second trial. Participants 106 
were also instructed to refrain from alcohol consumption and strenuous physical activity in 107 
this period. A pizza meal (5201 kJ) was consumed by participants between 19:00-20:00 the 108 
night before main trials to negate the influence of preceding food intake on morning appetite 109 
and appetite-related hormone concentrations (21). Adherence to these procedures was 110 
assessed by verbal confirmation.  111 
A schematic representation of the main trial procedures is shown in Figure 1. Participants 112 
arrived at the laboratory at approximately 08:30 after an overnight fast. A cannula was 113 
inserted into an antecubital vein 60 min before blood sampling commenced to mitigate any 114 
stress response caused by anxiety with the cannula (21). In the control trial, participants 115 
rested for 8 h, while in the exercise trial, participants ran at 70% of peak oxygen uptake for 116 
60 min and then rested for 7 h. Participants read, worked and watched TV through laptop and 117 
tablet devices while resting. Expired gas samples were collected into Douglas bags every 15 118 
min throughout the first hour in both trials for calculation of energy expenditure (22). 119 
Fixed test meal and buffet meal 120 
Participants consumed a standardized 5623 kJ (52% carbohydrate, 25% fat, 23% protein) test 121 
meal consisting of white rolls, butter, cheese, chips, chocolate slices and milkshake at 1.5 h. 122 
Participants were instructed to consume the meal within 20 minutes. 123 
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At 6.5 h, participants were provided with a buffet meal in a booth and instructed to eat ad 124 
libitum. Food items of the buffet meal were presented identically on each trial and included 125 
white and brown bread, butter, chicken, ham, lettuce, tomato, yoghurts, cookies and apples. 126 
Participants were instructed to eat until “comfortably full and satisfied” before leaving the 127 
eating booth. To minimize distractions that may influence food consumption, the buffet was 128 
provided in isolation and participants were not permitted the use of mobile phones or 129 
electronic devices. Items were provided in excess of expected consumption and participants 130 
were provided with more food items if requested. The amount of each food item consumed 131 
was calculated by measuring the weighted difference of all the food items before and after the 132 
meal. Manufacturer details were used to determine energy and macronutrient consumption.   133 
Appetite ratings 134 
Visual analogue scales (VAS) were used to assess subjective feelings of hunger, fullness, 135 
prospective food consumption and hedonic wanting of food (23,24). Measures were taken 136 
every 30 min from baseline to 5.0 h, and then at 6.5, 7.0, 7.5 and 8.0 h.  137 
Blood sampling 138 
Blood samples were collected into chilled EDTA monovettes (Sarstedt, Leicester, UK) every 139 
30 min from baseline to 4.0 h and subsequently at 5.0, 6.5 and 7.5 h to measure circulating 140 
concentrations of AG, DAG, total PYY and total GLP-1. Circulating leptin was measured 141 
from fasting samples only. Plasma BChE activity was determined from samples collected at 142 
0, 0.5 and 1 h in the control and exercise trials. All collected samples were immediately 143 
centrifuged at 2383g for 10 min at 4°C. After centrifugation, 100 µL of 0.5 mol/L 144 
hydrochloric acid was added per 900 µL of plasma supernatant to preserve DAG. To preserve 145 
the stability of AG, one monovette was treated with a 50 µL solution of PBS, P-146 
hydroxymercuribenzoic acid and sodium hydroxide. The plasma supernatant of this sample 147 
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was dispensed into a storage tube and 100 µL of 1 mol/L hydrochloric acid was added per 1 148 
ml of plasma. All samples were stored at -80°C until batch analysis.   149 
Biochemical analysis 150 
Enzyme-linked immunosorbent assays were used to measure circulating concentrations of 151 
AG, DAG (SCETI, Tokyo, Japan), total PYY, total GLP-1 (Millipore, Watford, UK) and 152 
leptin (R&D Systems, Abington, UK). The intra-assay variability was 4.3%, 3.5%, 1.9%, 153 
3.6% and 1.8% for AG, DAG, total PYY, total GLP-1 and leptin, respectively.  154 
Details of BChE analysis are documented in the Supplementary Methods. In short, BChE 155 
assays were performed based upon the cholinesterase assay method developed by Ellman 156 
(25), with butyrylthiocholine iodide as the enzymatic substrate. The intra-assay variability 157 
was 4.0% for BChE.  158 
Statistical analyses 159 
A sample size of 24 was chosen based on data suggesting that a 10 pmol/L reduction in 160 
circulating AG during exercise could be detected with > 80% power using a two-tailed t-test 161 
whilst assuming a SDdiff of 16 pmol/L and adopting an alpha value of 0.05 (26). Primary 162 
outcomes measured in this trial were AG, DAG, BChE activity, appetite and ad libitum 163 
energy intake, and secondary outcomes were total GLP-1, total PYY and leptin. To reduce 164 
day-to-day variability, appetite-related hormone concentrations and BChE were analyzed and 165 
presented as delta values. Appetite ratings, appetite-related hormone concentrations and 166 
BChE activity were analyzed using linear mixed models with trial (exercise or control), 167 
genotype (AA or TT) and time included as fixed factors. Total area under the curve (AUC) 168 
was calculated using the trapezoidal rule. For blood parameters, AUC was calculated during 169 
the intervention (0.0-1.0 h), post-test meal (1.5-3.5 h), afternoon (3.5-6.5 h) and post-buffet 170 
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meal (6.5-7.5 h) periods. AUC for subjective appetite ratings was calculated during the 171 
intervention (0.0-1.0 h), post-test meal (1.5-3.5 h), afternoon (3.5-6.5 h) and post-buffet meal 172 
(6.5-8.0 h) periods. Linear mixed models were used for trial (exercise or control) and 173 
genotype (AA or TT)  comparisons of AUC values and food consumption at the buffet meal. 174 
Post-hoc analysis was conducted using Holm-Bonferroni correction for multiple 175 
comparisons. Absolute standardized effect sizes (ES) were calculated by dividing the 176 
difference between the mean values (exercise vs. control or AAs vs. TTs) with the pooled 177 
standard deviation. An ES of 0.2 was considered the minimum important difference for all 178 
outcome measures, 0.5 moderate and 0.8 large (27). The 95% confidence intervals (CI) for 179 
mean absolute pairwise differences between experimental trials or genotype groups were 180 
calculated. Statistical significance was accepted as P < 0.05. Linear mixed models were 181 
conducted with trial order as a fixed effect which revealed no main or interactive effects for 182 
any outcome (P ≥ 0.073; data not shown). Unless stated otherwise, data presented in tables 183 
and figures are shown as mean ± SEM, while descriptive data are presented as mean ± SD. 184 
Data were analyzed using IBM SPSS Statistics for Windows software (version 23.0, IBM 185 
corporation, New York, USA). 186 
RESULTS 187 
Participant characteristics 188 
There were no differences between AAs and TTs for age, height, body mass, BMI, body fat 189 
%, lean body mass, waist circumference, eating behaviors, habitual physical activity levels or 190 
peak oxygen uptake (P ≥ 0.120) (Table 1). There were no differences in energy intake 191 
between AAs and TTs in the 24 h before the main trials (AA: 9516 ± 595 kJ vs TT: 9630 ± 192 
891 kJ; P = 0.716).  193 
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Treadmill running responses 194 
We observed no between-genotype differences in exercise responses for running speed (AA: 195 
11.1 ± 1.5 vs. TT: 11.3 ± 1.6 km/h; P = 0.782), heart rate (AA: 178 ± 13 vs. TT: 177 ± 12 196 
beats/min; P = 0.953), gross energy expenditure (AA: 3809 ± 366 vs. TT: 3568 ± 239 kJ; P = 197 
0.073) or percentage of peak oxygen uptake (AA: 71 ± 2 vs. TT: 70 ± 2%; P = 0.283). 198 
Circulating appetite-related hormones and BChE activity 199 
Fasting concentrations of AG, DAG, total GLP-1, total PYY and leptin at baseline were not 200 
different between genotype groups (P ≥ 0.127) or between trials (P ≥ 0.259) (Table 2). The 201 
fasting AG/DAG ratio and BChE activity were similar between trials (P ≥ 0.369), but the 202 
AG/DAG ratio and BChE were higher and lower, respectively, in AAs than TTs (ES ≥ 0.72, 203 
P ≤ 0.047) (Table 2). 204 
Linear mixed models for delta AG identified a main effect of trial (P < 0.001) and time (P < 205 
0.001) but not genotype (mean difference: -0.01 pmol/L, 95% CI -2.1, 2.1 pmol/L, P = 0.988) 206 
(Figure 2A). The main effect of trial revealed lower delta AG concentrations in the exercise 207 
than control trial (mean difference: -5.2 pmol/L, 95% CI -5.7, -4.7 pmol/L, ES = 0.77). 208 
Analysis also identified a genotype-by-time interaction (P = 0.007), but post-hoc analysis 209 
revealed no differences after Holm-Bonferroni adjustment (P ≥ 0.060). The AUC for delta 210 
AG was lower in the exercise than control trial during the intervention (0.0-1.0 h), post-test 211 
meal (1.5-3.5 h) and afternoon (3.5-6.5 h) periods (all ES ≥ 0.53, P ≤ 0.001) (Table 3). The 212 
magnitude of reduction in AUC for delta AG after exercise was greater in AAs than TTs 213 
during the post-test meal period (1.5-3.5 h; -24.0 pmol/L·h (ES = 3.72) vs. -14.3 pmol/L·h 214 
(ES = 1.71), respectively; genotype-by-trial interaction P = 0.023) (Table 3). Post-hoc 215 
analysis of the post-test meal period revealed higher AUC delta AG in AAs compared to TTs 216 
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in the control trial (ES = 1.25, P = 0.011), but no between-genotype differences were seen in 217 
the exercise trial (ES = 0.03, P = 0.951).  218 
There was a main effect of trial (P < 0.001) and time (P < 0.001) but not genotype (mean 219 
difference: 9.5 pmol/L, 95% CI -5.3, 24.3 pmol/L, P = 0.197) for delta DAG (Figure 2B). 220 
The main effect of trial revealed lower delta DAG concentrations in the exercise than control 221 
trial (mean difference: -16.7 pmol/L, 95% CI -19.8, -13.5 pmol/L, ES = 0.44). The magnitude 222 
of reduction in delta DAG concentrations after exercise was greater in TTs than AAs (-25.2 223 
pmol/L (ES = 0.58) vs. -8.9 pmol/L (ES = 0.26), respectively; genotype-by-trial interaction P 224 
< 0.001). The AUC for delta DAG was lower in the exercise than control trial during the 225 
intervention (0.0-1.0 h), post-test meal (1.5-3.5 h) and afternoon (3.5-6.5 h) periods (all ES ≥ 226 
0.29, P ≤ 0.028) (Table 3). The magnitude of reduction in AUC for delta DAG after exercise 227 
was greater in TTs than AAs during the intervention period (0.0-1.0 h; -82.4 pmol/L·h (ES = 228 
2.47) vs. -46.2 pmol/L·h (ES = 1.66), respectively; genotype-by-trial interaction P = 0.042) 229 
and post-test meal period (1.5-3.5 h; -100.8 pmol/L·h (ES = 1.75) vs. -35.0 pmol/L·h (ES = 230 
0.76), respectively; genotype-by-trial interaction P = 0.025) (Table 3).  231 
Linear mixed models for the delta AG/DAG ratio identified a main effect of trial (P < 0.001) 232 
and time (P < 0.001) but not genotype (mean difference: -0.006, 95% CI -0.015, 0.003, P = 233 
0.192) (Figure 2C). The main effect of trial revealed the delta AG/DAG ratio was lower in 234 
the exercise than control trial (mean difference: -0.025, 95% CI -0.029, -0.022, ES = 0.88). 235 
The magnitude of reduction in the delta AG/DAG ratio after exercise was greater in AAs than 236 
TTs at time points between 0.5 h to 2.5 h (genotype-by-trial-by-time interaction, P = 0.004). 237 
The AUC for the AG/DAG ratio was lower in the exercise than control trial during the 238 
intervention, post-test meal, and post-buffet meal periods (all ES ≥ 0.89, P ≤ 0.006) (Table 3). 239 
The magnitude of reduction in AUC for the delta AG/DAG ratio after exercise was greater in 240 
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AAs than TTs during the intervention period (0.0-1.0 h; -0.119 (ES = 8.03) vs. -0.068 (ES = 241 
2.72), respectively; genotype-by-trial interaction P = 0.004) and post-test meal period (1.5-242 
3.5 h; -0.159 (ES = 2.57) vs. -0.016 (ES = 0.24), respectively; genotype-by-trial interaction P 243 
= 0.001) (Table 3). Post-hoc analysis of the intervention period revealed a similar AUC delta 244 
AG/DAG ratio between groups in the control trial (ES = 0.26, P = 0.518), but the AG/DAG 245 
ratio was lower in AAs compared to TTs in the exercise trial (ES = 1.75, P < 0.001). Post-hoc 246 
analysis in the post-test meal period indicated that AAs exhibited higher AUC delta AG/DAG 247 
in the control trial (ES = 1.27, P = 0.048) but lower AUC delta AG/DAG in the exercise trial 248 
(ES = 1.24, P = 0.018) compared to TTs.  249 
There was a main effect of trial (P < 0.001) and time (P < 0.001) but not genotype (mean 250 
difference: 2.1 pmol/L, 95% CI -2.3, 6.6 pmol/L, P = 0.335) for delta total GLP-1 (Figure 251 
3A). The main effect of trial revealed higher delta total GLP-1 concentrations in the exercise 252 
than control trial (mean difference: 13.8 pmol/L, 95% CI 12.5, 15.1 pmol/L, ES = 1.14). 253 
Analysis also identified a genotype-by-time interaction (P = 0.002), but post hoc analysis 254 
showed no differences after Holm-Bonferroni adjustment (P ≥ 0.092). The AUC for delta 255 
total GLP-1 was higher in the exercise than control trial during all time periods (all ES ≥ 256 
0.50, P ≤ 0.044), and higher in AAs than TTs during the post-buffet meal period (6.5-7.5 h; 257 
ES = 0.86, P = 0.011) (Table 4).  258 
A main effect of trial (P < 0.001) and time (P < 0.001) but not genotype (mean difference: 259 
10.3 pg/mL, 95% CI -8.9, 29.4 pg/mL, P = 0.278) was detected for delta total PYY (Figure 260 
3B). The main effect of trial revealed higher delta total PYY concentrations in the exercise 261 
than control trial (mean difference: 24.8 pg/mL, 95% CI 19.8, 29.9 pg/mL, ES = 0.50). The 262 
AUC for delta total PYY was higher in the exercise than control trial during the intervention 263 
(0.0-1.0 h; ES = 3.08, P < 0.001) and post-test meal (1.5-3.5 h; ES = 1.56, P < 0.001) periods, 264 
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and higher in AAs than TTs during the post-buffet meal period (6.5-7.5 h; ES = 0.78, P = 265 
0.029) (Table 4). 266 
Analysis for delta BChE identified a main effect of time (P < 0.001) and trial (P = 0.004), 267 
with elevated BChE activity in the exercise trial compared to the control trial (mean 268 
difference: 0.072 KU/L, 95% CI 0.024, 0.120 KU/L, ES = 0.37) (Figure 4). There was, 269 
conversely, no main effect of genotype (mean difference: -0.016 KU/L, 95% CI -0.095, 0.063 270 
KU/L, P = 0.681), and no two-way or three-way interactions for BChE activity (P ≥ 0.094) 271 
(Figure 4).  272 
Appetite ratings 273 
Linear mixed models for each appetite perception identified a main effect of trial (P ≤ 0.002) 274 
and time (P < 0.001) but not genotype (P ≥ 0.072) (Figure 5). The main effect of trial for 275 
each perception revealed suppressed appetite in the exercise compared with the control trial 276 
(all ES ≥ 0.12). Analysis also identified a genotype-by-time interaction for each appetite 277 
perception (P < 0.001) (Figure 5). Post-hoc analysis of the genotype-by-time interaction 278 
revealed higher ratings of hunger and hedonic wanting of food and lower ratings of fullness 279 
in AAs than TTs at time points between 3.0 to 4.0 h (all ES ≥ 1.04, P ≤ 0.033). There were no 280 
between-genotype differences at any time point for prospective food consumption after 281 
Holm-Bonferroni correction (P ≥ 0.130). A main effect of trial for AUC values in the 282 
intervention period (0.0-1.0 h) revealed lower ratings of hunger, prospective food 283 
consumption and hedonic wanting of food and higher ratings of fullness in the exercise than 284 
control trial (all ES ≥ 1.14, P < 0.001) (Table 5). A main effect of genotype for AUC values 285 
in the post-test meal (1.5-3.5 h) and afternoon (3.5-6.5 h) periods revealed higher ratings of 286 
hunger, prospective food consumption and hedonic wanting of food but lower ratings of 287 
fullness in AAs than TTs (all ES ≥ 0.81, P ≤ 0.045) (Table 5). 288 
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Buffet meal 289 
Absolute energy intake was greater in AAs than TTs (ES = 0.86, P = 0.049), but was similar 290 
between the exercise and control trials (P = 0.282) (Table 6). Relative energy intake was 291 
substantially lower in the exercise than control trial (ES = 1.84, P < 0.001), and tended to be 292 
greater in AAs than TTs (ES = 0.80, P = 0.081). Protein intake was higher in AAs than TTs 293 
(ES = 0.94, P = 0.032), and intakes of carbohydrate (ES = 0.73, P = 0.074) and fat (ES = 294 
0.82, P = 0.070) were meaningfully, albeit not statistically, greater in AAs than TTs. Linear 295 
mixed models revealed no genotype-by-trial interactions for energy or macronutrient intakes 296 
(P ≥ 0.207). 297 
DISCUSSION 298 
The primary findings of this study are that normal weight males homozygous for the obesity-299 
risk FTO rs9939609 A-allele displayed lower fasting BChE activity and higher postprandial 300 
AG and AG/DAG ratio which coincided with higher postprandial appetite and ad libitum 301 
energy intake compared to TTs. A single bout of exercise increased BChE activity and 302 
suppressed circulating AG. Importantly, the exercise-induced suppression of the AG/DAG 303 
ratio was greater in AA versus TT individuals, negating the differences in ghrelin seen in the 304 
control trial. Exercise transiently suppressed appetite and did not lead to compensatory 305 
increases in appetite or energy intake after the test meal in either genotype group. 306 
Elevated AG and AG/total ghrelin ratio profiles in AAs have been implicated in their higher 307 
obesity risk (7,28). More recently, DAG has been shown to antagonize the orexigenic effects 308 
of AG, and the AG/DAG ratio has been suggested as a key determinant of appetite, energy 309 
intake and body weight (29,30). Thus, our novel finding of a higher AG/DAG ratio in AAs 310 
compared to TTs supports the concept that ghrelin may play an aetiopathogenic role in the 311 
higher energy intake and obesity-risk associated with the A-allele of rs9939609. However, we 312 
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showed that exercise suppresses AG and the AG/DAG ratio and offsets these rs9939609 313 
genotype differences. An acute reduction in AG during exercise has been shown before (8), 314 
but our study is the first to show differences between AA and TT individuals during exercise 315 
and immediately after the test meal. Specifically, in response to exercise, we found a greater 316 
reduction in the AG/DAG ratio during the exercise intervention period, and in AG and the 317 
AG/DAG ratio after provision of the test meal (1.5-3.5 h) in AAs compared with TTs. 318 
Physical activity attenuates the effect of rs9939609 A obesity-risk allele on adiposity (31), 319 
but our study may offer insights into the mechanisms of this genotype-lifestyle interaction 320 
(31). That is, the greater exercise-induced suppression of AG and the AG/DAG ratio in AAs 321 
could partly explain the greater weight loss seen in carriers of the risk genotype with exercise 322 
interventions (32,33). 323 
The elevation inhigher BChE activity in response to exercise supports previous findings 324 
suggesting that an acute bout of walking/running elevated plasma BChE activity (16). The 325 
mechanisms underlying this response require further study, though it may be that the transient 326 
increase in inflammatory markers could be implicated (34). It is possible that the elevation 327 
inhigher BChE activity during exercise compared to rest increased AG hydrolysis to DAG, 328 
providing a plausible mechanism for the exercise-induced reduction of plasma AG 329 
concentrations. However, we also showed that plasma DAG concentrations were suppressed 330 
during exercise, indicating that an attenuation of ghrelin release may also be implicated in 331 
response to exercise. Therefore, it is likely that several mechanisms are involved in the 332 
exercise-stimulated suppression of AG. 333 
Another novel finding of lower fasting BChE activity in AA compared to TT individuals 334 
offers a potential explanation for the higher AG/DAG ratio and energy intake observed in AA 335 
versus TT individuals. BChE activity increases AG hydrolysis in plasma, leading to greater 336 
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DAG and a lower AG/DAG ratio, which has been linked to lower energy consumption and 337 
lower adiposity in mice (14). In contrast to our findings, the FTO rs9939609 A-allele has 338 
previously been associated with higher BChE activity, yet this relationship was diminished 339 
when BMI was controlled (35). The careful matching of AAs and TTs in our study may have 340 
improved the sensitivity to detect differences in the FTO rs9939609 genotype, particularly as 341 
age, sex, substance abuse, physical activity and smoking have been shown to affect BChE 342 
activity (36,37). 343 
Considering the present study identified transient changes in BChE activity and ghrelin 344 
profiles and both outcomes are implicated in several metabolic and neuronal functions 345 
(38,39), establishing the precise interplay between plasma ghrelin and BChE activity 346 
represents an avenue for future scientific enquiry. Our Nevertheless, our findings may 347 
expound a complex set of mechanisms that link FTO and obesity. FTO encodes FTO protein, 348 
which demethylates the nucleoside N6-methyladenosine in RNA and, in turn, regulates 349 
mRNA export, RNA metabolism and RNA splicing (7,38). Ghrelin, ghrelin-O-350 
acyltransferase and BChE mRNA have all been identified as targets for FTO demethylation 351 
and this could offer a mechanistic link between FTO rs9939609 and our findings (7). Indeed, 352 
AAs have been reported to exhibit higher FTO protein expression compared to TTs, 353 
indicating a potential direct mechanistic link between rs9939609 A-allele, the FTO protein, 354 
circulating ghrelin, lower BChE activity, higher energy intake and obesity. Taken together, 355 
this could suggest that therapeutic interventions augmenting BChE activity may offer a 356 
potential strategy that could assist with weight management in AA individuals. 357 
Acute studies report that appetite is transiently suppressed during exercise and compensatory 358 
changes in these perceptions and energy intake do not occur (8–10). Our results are 359 
consonant with these findings, and we demonstrated that the appetite suppression during 360 
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exercise was comparable in AAs and TTs and ad libitum energy intake was unaltered after 361 
exercise in both genotype groups. We also showed that AAs exhibited greater perceptions of 362 
appetite in the 4.5 hours after the test meal and consumed a higher energy intake and protein 363 
at the buffet meal. Our results are in agreement with studies indicating that individuals with 364 
the A-allele of rs9939609 exhibit reduced satiety (4,7,39), higher food intake (5,6) and 365 
elevated protein intake (40). It seems likely that the greater postprandial appetite displayed by 366 
AAs plays a role in the higher energy intake exhibited by this group. The FTO-linked change 367 
in protein consumption could be related to the role FTO plays in sensing amino acids (41). It 368 
is, nevertheless, noteworthy that there was a tendency for AA individuals to consume more 369 
carbohydrate and fat at the buffet meal. This indicates that the FTO rs9939609 A-allele is 370 
associated with a higher intake of all macronutrients and this may have been detected with a 371 
larger sample size.  372 
In line with previous studies, total GLP-1 and total PYY concentrations were elevated during 373 
and immediately after exercise (9,11), and this rise was similar in AAs and TTs. At most 374 
periods of the day, concentrations of the satiety hormones, leptin, total GLP-1 and total PYY 375 
were not influenced by the FTO rs9939609 variant, supporting previous research (7). The 376 
only exception was after the buffet meal, where the elevations in total GLP-1 and total PYY 377 
were greater in AAs than TTs. However, rather than any effect of the FTO rs9939609 variant, 378 
this is likely to reflect the greater energy and protein intake seen in AAs at the buffet meal 379 
(42,43). Our data therefore bolster evidence suggesting that AAs and TTs exhibit no 380 
differences in circulating PYY and GLP-1 concentrations after standardized food intake (7). 381 
Our study is not without limitations. First, we studied normal weight males who exhibited 382 
high peak oxygen uptake. It is unclear if the responses observed would be evident in other 383 
populations such as women, older adults, and in cohorts with overweight and obesity. It is 384 
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also not known if the changes observed in response to exercise would be seen during exercise 385 
protocols lower in time and intensity. Hence, though our results may be important for obesity 386 
prevention, additional work is needed in other populations and in response to exercise 387 
regimens performed more frequently amongst the general population, especially in those who 388 
are overweight or obese. Second, we only examined BChE activity during the first hour of 389 
the main trials. Although this allowed us to evaluate the transient influence of exercise, 390 
further work is needed to elucidateinvestigating the longer-term changes in BChE activity 391 
after exercise and meal intake is required to determine how exercise- and meal-induced 392 
alterations in ghrelin profiles are influenced by BChE activity.  393 
In conclusion, our study showed carriers of the FTO rs9939609 A-allele display lower fasting 394 
BChE activity, higher post-meal AG and AG/DAG ratio, and higher energy intake compared 395 
to TTs. However, a single bout of exercise enhances BChE activity, and corrects the 396 
attenuated meal-induced suppression of AG in AAs, while the energy cost of exercise did not 397 
engender an increase in energy intake in either genotype group. These findings suggest that 398 
exercise could be a strategy to ameliorate the adiposity-related traits mediated by the obesity-399 
linked FTO rs9939609 SNP. 400 
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Table 1. Characteristics of the AA and TT participants. 
 AA (n = 12) TT (n = 12) 
Main effect genotype 
TT vs AA 
Mean difference (95% CI1) 
Age (years) 20.9 ± 3.5 21.3 ± 3.6 -0.4 (-3.4, 2.6) 
Height (cm) 181.6 ± 5.8 177.5 ± 6.5 4.1 (-1.2, 9.3) 
Body mass (kg) 77.6 ± 11.3 73.8 ± 6.9 3.9 (-4.1, 11.8) 
BMI (kg/m2) 23.5 ± 2.7 23.5 ± 2.3 0.01 (-2.1, 2.1) 
Body fat (%) 15.6 ± 5.1 13.9 ± 4.7 1.7 (-2.4, 5.9) 
Lean body mass (kg) 65.2 ± 7.4 63.3 ± 4.2 1.9 (-3.2, 7.0) 
Waist circumference (cm) 80.3 ± 6.1 78.1 ± 4.1 2.2 (-2.2, 6.6) 
Three-Factor Eating 
Questionnaire 
   
Dietary restraint 7.7 ± 4.5 7.6 ± 3.9 0.1 (-3.5, 3.6) 
Dietary disinhibition 6.3 ± 2.3 6.6 ± 1.6 -0.3 (-1.9, 1.4) 
Hunger 6.5 ± 2.1 6.9 ± 1.7 -0.4 (-2.0, 1.2) 
Total physical activity 
(metabolic equivalent 
minutes/week) 
4368 ± 1968 4790 ± 2728 -423 (-2436, 1591) 
Peak oxygen uptake 
(mL/kg/min) 
55.8 ± 5.8 56.6 ± 4.9 -0.8 (-5.4, 3.7) 
Values are mean ± SD. Data were analyzed using linear mixed models with genotype (AA or 
TT) included as a fixed factor.  
1 95% confidence interval of the mean absolute difference between the genotype groups. No 
differences were identified between genotype groups (P ≥ 0.120).
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Table 2. Fasting appetite-related hormone concentrations and butyrylcholinesterase activity at baseline for AAs and TTs in the control and 
exercise trials. 
   AA (n = 12) TT (n = 12) Main effect trial 
Control vs exercise  
Mean difference (95% 
CI1) 
Main effect genotype 
TT vs AA 
Mean difference (95% CI2)   Control Exercise Control Exercise 
Acyl-ghrelin (pmol/L) 22.4 ± 1.4 22.5 ± 1.3 20.9 ± 1.5 21.1 ± 1.5 0.1 (-0.4, 0.6) 1.4 (-2.7, 5.6) 
Des-acyl-ghrelin 
(pmol/L) 
135.0 ± 9.3 134.1 ± 8.7 156.3 ± 10.6 155.4 ± 10.0 -0.9 (-6.1, 4.3) -21.3 (-49.1, 6.5) 
Acyl-/des-acyl-ghrelin 
ratio 
0.167 ± 0.005 0.169 ± 0.006 0.134 ± 0.004 0.135 ± 0.003 0.002 (-0.002, 0.006) 0.034 (0.021, 0.047)3 
Total GLP-1 (pmol/L) 26.2 ± 2.2 25.4 ± 2.2 32.3 ± 3.3 31.7 ± 3.5 -0.8 (-2.1, 0.6) -6.2 (-14.6, 2.1) 
Total PYY (pg/mL) 156.2 ± 12.2 163.1 ± 12.7 187.4 ± 20.8 185.4 ± 17.8 2.5 (-11.3, 16.3) -26.8 (-72.5, 18.9) 
Leptin (pg/mL) 1216 ± 183 1358 ± 200 1343 ± 273 1267 ± 214 33 (-133, 198) -18 (-658, 622) 
Butyrylcholinesterase 
activity (KU/L) 
1.481 ± 0.060 1.404 ± 0.062 1.613 ± 0.084 1.635 ± 0.071 -0.027 (-0.129, 0.074) -0.181 (-0.360, -0.003)3 
Values are mean ± SEM. Data were analyzed using linear mixed models with trial (exercise or control) and genotype (AA or TT) included as 
fixed factors.  
1 95% confidence interval of the mean absolute difference between the experimental trials. 
2 95% confidence interval of the mean absolute difference between the genotype groups. 
3 Significant mMain effect of genotype (P < 0.05).  
Linear mixed models revealed no main effects of trial (P ≥ 0.259) and no genotype-by-trial interactions (P ≥ 0.185). 
GLP-1, glucagon-like peptide-1; PYY, peptide YY. 
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Table 3. Time-averaged total area under the curve for delta acyl-ghrelin, des-acyl-ghrelin and the acyl-/des-acyl-ghrelin ratio for AAs and TTs 
in the control and exercise trials. 
  AA (n = 12) TT (n = 12) Main effect trial 
Control vs exercise 
Mean difference (95% 
CI1) 
Main effect genotype 
TT vs AA 
Mean difference (95% 
CI2) 
  
Control Exercise Control Exercise 
Δ AG (pmol/L·h)       
Intervention period 3.8 ± 0.7 -17.4 ± 1.6 5.2 ± 0.9 -15.0 ± 1.5 -20.7 (-23.4, -18.0)3 -1.9 (-4.3, 0.5) 
Post-test meal -5.6 ± 1.9 -29.6 ± 3.5 -15.0 ± 2.4 -29.3 ± 2.7 -19.2 (-23.3, -15.1)3,4 4.5 (-2.1, 11.2)4 
Afternoon -38.9 ± 6.9 -52.1 ± 8.6 -40.2 ± 7.6 -53.9 ± 7.1 -13.4 (-19.8, -7.1)3 1.6 (-19.7, 22.9) 
Post-buffet meal -8.9 ± 2.5 -11.6 ± 2.7 -7.5 ± 2.7 -10.1 ± 1.8 -2.6 (-5.2, 0.1) -1.4 (-8.1, 5.2) 
Δ DAG (pmol/L·h)       
Intervention period 18.0 ± 3.5 -28.2 ± 10.8 27.0 ± 7.8 -55.4 ± 11.2 -64.3 (-81.7, -46.9)3,4 9.1 (-10.3, 28.5)4 
Post-test meal -66.3 ± 13.9 -101.4 ± 23.4 -66.6 ± 16.6 -167.4 ± 18.4 -67.9 (-96.2, -39.7)3,4 33.2 (-13.1, 79.4)4 
Afternoon -255.6 ± 49.1 -271.4 ± 48.5 -317.4 ± 54.5 -407.6 ± 61.2 -53.0 (-99.6, -6.4)3 99.0 (-51.1, 249.1) 
Post-buffet meal -73.2 ± 19.4 -46.3 ± 13.2 -76.7 ± 22.6 -74.7 ± 15.9 12.3 (-5.8, 30.5) 11.8 (-37.1, 60.6) 
Δ AG/DAG ratio (h)       
Intervention period 0.006 ± 0.004 -0.114 ± 0.008 0.011 ± 0.007 -0.057 ± 0.010 -0.093 (-0.110, -0.077)3,4 -0.031 (-0.047, -0.015)4,5 
Post-test meal 0.035 ± 0.019 -0.124 ± 0.015 -0.048 ± 0.019 -0.063 ± 0.013 -0.087 (-0.124, -0.050)3,4 0.010 (-0.021, 0.042)4 
Afternoon 0.043 ± 0.036 -0.085 ± 0.039 0.022 ± 0.036 0.016 ± 0.041 -0.067 (-0.138, 0.004) -0.040 (-0.127, 0.046) 
Post-buffet meal 0.037 ± 0.022 -0.040 ± 0.016 0.020 ± 0.011 -0.005 ± 0.008 -0.051 (-0.085, -0.016)3 -0.010 (-0.037, 0.016) 
Values are mean ± SEM. Intervention period covers 0.0-1.0 h; post-test meal covers 1.5-3.5 h; afternoon period covers 3.5-6.5 h; post-buffet 
meal covers 6.5-7.5 h. Data were analyzed using linear mixed models with trial (exercise or control) and genotype (AA or TT) included as fixed 
factors.  
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1 95% confidence interval of the mean absolute difference between the experimental trials. 
2 95% confidence interval of the mean absolute difference between the genotype groups. 
3 Significant mMain effect of trial (P < 0.05). 
4 Significant gGenotype-by-trial interaction (P < 0.05). 
5 Significant mMain effect of genotype (P < 0.05). 
AG, acyl-ghrelin; DAG, des-acyl-ghrelin.  
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Table 4. Time-averaged total area under the curve for delta concentrations of total glucagon-like peptide-1 and total peptide YY for AAs and 
TTs in the control and exercise trials. 
 AA (n = 12) TT (n = 12) Main effect trial 
Control vs exercise 
Mean difference (95% CI1) 
Main effect genotype 
TT vs AA 
Mean difference (95% CI2)   Control Exercise Control Exercise 
Δ Total GLP-1 (pmol/L·h)       
Intervention period -3.8 ± 0.9 15.0 ± 1.8 -6.5 ± 1.2 10.7 ± 2.4 18.0 (14.7, 21.4)3 3.5 (-0.2, 7.2) 
Post-test meal 34.2 ± 8.3 107.0 ± 12.1 21.4 ± 7.0 112.3 ± 8.0 81.6 (64.9, 98.3)3 4.0 (-16.8, 24.8) 
Afternoon 97.0 ± 22.4 142.8 ± 15.2 80.0 ± 17.4 144.6 ± 15.4 55.2 (27.0, 83.4)3 7.6 (-36.5, 51.7) 
Post-buffet meal 33.0 ± 7.8 44.6 ± 5.2 15.7 ± 4.8 25.0 ± 5.6 10.4 (0.3, 20.5)3 18.6 (4.7, 32.4)4 
Δ Total PYY (pg/mL·h)       
Intervention period -14.7 ± 8.3 51.5 ± 13.3 -18.3 ± 3.8 53.7 ± 13.3 69.1 (48.2, 90.0)3 0.7 (-21.8, 23.2) 
Post-test meal 105.7 ± 24.0 215.2 ± 34.6 61.1 ± 24.7 207.3 ± 30.7 128.4 (74.3, 182.6)3 25.7 (-40.0, 91.3) 
Afternoon 507.5 ± 82.9 536.4 ± 85.8 394.0 ± 85.4 458.7 ± 67.8 46.8 (-76.5, 170.0) 95.6 (-106.9, 298.1) 
Post-buffet meal 198.4 ± 24.5 166.6 ± 21.7 108.9 ± 22.0 131.8 ± 23.7 -4.0 (-43.2, 35.3) 61.6 (7.1, 116.2)4 
Values are mean ± SEM. Intervention period covers 0.0-1.0 h; post-test meal covers 1.5-3.5 h; afternoon period covers 3.5-6.5 h; post-buffet 
meal covers 6.5-7.5 h. Data were analyzed using linear mixed models with trial (exercise or control) and genotype (AA or TT) included as fixed 
factors. 
1 95% confidence interval of the mean absolute difference between the experimental trials. 
2 95% confidence interval of the mean absolute difference between the genotype groups. 
3 Significant mMain effect of trial (P < 0.05). 
4 Significant mMain effect of genotype (P < 0.05). 
Linear mixed models revealed no genotype-by-trial interactions (P ≥ 0.169).  
GLP-1, glucagon-like peptide-1, PYY, peptide YY.  
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Table 5. Time-averaged total area under the curve for appetite perceptions for AAs and TTs 
in the control and exercise trials. 
  AA (n = 12) TT (n =12) Main effect trial 
Control vs exercise 
Mean difference 
(95% CI1) 
Main effect genotype 
TT vs AA 
Mean difference 
(95% CI2) 
   
Control Exercise Control Exercise 
Hunger (mm·h)        
Intervention 68 ± 4 39 ± 5 80 ± 3 53 ± 6 -27 (-37, -18)3 -13 (-24, -2)4 
Post-test meal 83 ± 8 87 ± 6 60 ± 6 60 ± 5 2 (-10, 13) 25 (10, 40)4 
Afternoon 172 ± 14 192 ± 13 138 ± 10 144 ± 14 13 (-4, 30) 41 (7, 74)4 
Post-buffet meal 35 ± 4 44 ± 4 32 ± 3 31 ± 3 4 (-2, 9) 8 (-1, 17) 
Fullness (mm·h)       
Intervention 21 ± 4 39 ± 5 13 ± 3 25 ± 5 15 (9, 21)3 11 (-0.2, 23) 
Post-test meal 113 ± 7 116 ± 8 132 ± 6 137 ± 5 4 (-6, 15) -20 (-37, -3)4 
Afternoon 108 ± 13 102 ± 13 142 ± 12 141 ± 12 -4 (-27, 19) -37 (-66, -8)4 
Post-buffet meal 99 ± 4 101 ± 3 112 ± 3 110 ± 3 0 (-4, 3) -11 (-20, -2)4 
Prospective food 
consumption (mm·h) 
      
Intervention 77 ± 4 51 ± 5 80 ± 4 58 ± 6 -24 (-32, -16)3 -6 (-17, 6) 
Post-test meal 99 ± 8 102 ± 7 77 ± 8 71 ± 9 -2 (-11, 8) 26 (5, 48)4 
Afternoon 186 ± 14 205 ± 11 163 ± 12 157 ± 16 6 (-10, 23) 36 (1, 71)4 
Post-buffet meal 46 ± 5 52 ± 5 39 ± 3 43 ± 6 5 (-1, 11) 7 (-6, 21) 
Hedonic wanting of 
food (mm·h) 
      
Intervention 78 ± 4 49 ± 6 83 ± 4 57 ± 6 -28 (-38, -19)3 -7 (-19, 6) 
Post-test meal 107 ± 10 107 ± 6 81 ± 9 78 ± 10 -2 (-12, 8) 28 (4, 52)4 
Afternoon 201 ± 12 219 ± 9 161 ± 13 158 ± 17 8 ( -11, 26) 51 (17, 84)4 
Post-buffet meal 55 ± 7 61 ± 5 52 ± 6 51 ± 7 2 (-5, 10) 7 (-10, 23) 
Values are mean ± SEM. Intervention period covers 0.0-1.0 h; post-test meal covers 1.5-3.5 
h; afternoon period covers 3.5-6.5 h; post-buffet meal covers 6.5-8.0 h. Data were analyzed 
using linear mixed models with trial (exercise or control) and genotype (AA or TT) included 
as fixed factors. 
1 95% confidence interval of the mean absolute difference between the experimental trials. 
2 95% confidence interval of the mean absolute difference between the genotype groups. 
3 Significant mMain effect of trial (P < 0.05). 
4 Significant mMain effect of genotype (P < 0.05). 
Linear mixed models revealed no genotype-by-trial interactions (P ≥ 0.061).
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Table 6. Energy and macronutrient intakes at the buffet meal for AAs and TTs in the control 
and exercise trials. 
  AA (n = 12) TT (n = 12) Main effect trial 
Control vs 
exercise 
Mean difference 
(95% CI1) 
Main effect 
genotype  
TT vs AA 
Mean difference 
(95% CI2) 
  Control Exercise Control Exercise 
Absolute 
energy intake 
(kJ) 
5230 ± 
576 
5554 ± 
627 
3788 ± 
463 
3897 ± 
490 
217 (-191, 625) 1549 (10, 3088)3 
Relative 
energy intake 
(kJ) 
5139 ± 
596 
1888 ± 
671 
3710 ± 
448 
532 ± 
488 
-3214 (-3674, -
2755)4 
1393 (-186, 2973) 
Carbohydrate 
(g) 
160 ± 
18 
162 ± 17 117 ± 16 119 ± 17 3 (-12, 18) 43 (-4, 90) 
Protein (g) 48 ± 4 52 ± 5 36 ± 4 37 ± 5 3 (-1, 7) 14 (1, 26)3 
Fat (g) 47 ± 7 52 ± 8 33 ± 4 34 ± 4 3 (-0.2, 7) 16 (-1, 34) 
Values are mean ± SEM. Relative energy intake is energy intake at the buffet meal minus the 
gross energy expenditure of the intervention period (0.0-1.0 h). Data were analyzed using 
linear mixed models with trial (exercise or control) and genotype (AA or TT) included as 
fixed factors. 
1 95% confidence interval of the mean absolute difference between the experimental trials. 
2 95% confidence interval of the mean absolute difference between the genotype groups. 
3 Significant mMain effect of genotype (P < 0.05). 
4 Significant mMain effect of trial (P < 0.05). 
Linear mixed models revealed no genotype-by-trial interactions (P ≥ 0.207). 
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Figure legends 
Figure 1. Schematic representation of the main trials. 
Figure 2. Δ AG concentrations (A), DAG concentrations (B) and AG/DAG ratio (C) in AAs 
(n = 12) and TTs (n = 12) during the control (AAs: solid line, ■; TTs: solid line, ▲) and 
exercise (AAs: dashed line, □; TTs: dashed line, ∆) trials. Dotted rectangle indicates 
exercise, horizontally dashed rectangle indicates standardized test meal, vertically dashed 
rectangle indicates buffet meal. Data are represented as mean ± SEM. Data were analyzed 
using linear mixed models with trial (exercise or control), genotype (AA or TT) and time 
included as fixed factors. Δ AG: main effect trial P < 0.001, main effect time P < 0.001, 
genotype-by-time interaction P = 0.007; Δ DAG: main effect trial P < 0.001, main effect time 
P < 0.001, genotype-by-trial interaction P < 0.001; Δ AG/DAG ratio: main effect trial P < 
0.001, main effect time P < 0.001, genotype-by-trial interaction P < 0.001, genotype-by-time 
interaction P = 0.001, genotype-by-trial-by-time interaction P = 0.004. Linear mixed models 
for Δ AG, Δ DAG and Δ AG/DAG ratio revealed no main effect of genotype (all P ≥ 0.192) 
or other interactive effects (P ≥ 0.083). AG, acyl-ghrelin; DAG, des-acyl-ghrelin.  
Figure 3. Δ Total GLP-1 (A) and total PYY (B) concentrations in AAs (n = 12) and TTs (n = 
12) during the control (AAs: solid line, ■; TTs: solid line, ▲) and exercise (AAs: dashed 
line, □; TTs: dashed line, ∆) trials. Dotted rectangle indicates exercise, horizontally dashed 
rectangle indicates standardized test meal, vertically dashed rectangle indicates buffet meal. 
Data are represented as mean ± SEM. Data were analyzed using linear mixed models with 
trial (exercise or control), genotype (AA or TT) and time included as fixed factors. Δ total 
GLP-1: main effect trial P < 0.001, main effect time P < 0.001, genotype-by-time interaction 
P = 0.002; Δ total PYY: main effect trial P < 0.001, main effect time P < 0.001. Linear mixed 
models for Δ total GLP-1 and Δ total PYY revealed no main effect of genotype (all P ≥ 
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0.278) or other interactive effects (P ≥ 0.089). GLP-1, glucagon-like peptide-1, PYY, peptide 
YY.  
Figure 4. Δ Plasma BChE activity in AAs (n = 12) and TTs (n =12) during the control (AAs: 
solid line, ■; TTs: solid line, ▲) and exercise (AAs: dashed line, □; TTs: dashed line, ∆) 
trials at 0.5 and 1.0 h. Dotted rectangle indicates exercise. * P = 0.004 for main effect of trial. 
Data are represented as mean ± SEM. Data were analyzed using linear mixed models with 
trial (exercise or control), genotype (AA or TT) and time included as fixed factors. Δ BChE 
activity: main effect trial P = 0.004, main effect time P < 0.001. Linear mixed models for Δ 
BChE activity revealed no main effect of genotype (P = 0.681) or interactive effects (P ≥ 
0.094). BChE, butyrylcholinesterase.  
Figure 5. Hunger (A), fullness (B), prospective food consumption (C) and hedonic wanting 
of food (D) in AAs (n = 12) and TTs (n = 12) during the control (AAs: solid line, ■; TTs: 
solid line, ▲) and exercise (AAs: dashed line, □; TTs: dashed line, ∆) trials. Dotted rectangle 
indicates exercise, horizontally dashed rectangle indicates standardized test meal, vertically 
dashed rectangle indicates buffet meal. Data are represented as mean ± SEM. Data were 
analyzed using linear mixed models with trial (exercise or control), genotype (AA or TT) and 
time included as fixed factors. All appetite perceptions: main effect trial P ≤ 0.002, main 
effect time P < 0.001, genotype-by-time interaction P < 0.001. Linear mixed models for each 
appetite perception revealed no main effect of genotype (P ≥ 0.072) or other interactive 
effects (P ≥ 0.094).  
